Roche to increase its payroll in Switzerland by 0.9 percent

Basel, 09 December 2015

Roche is increasing the payroll for its workforce of over 14,000 employees in Switzerland by 0.9 percent with effect from 1 April 2016. This latest increase acknowledges the great commitment of our employees, taking into account the company's positive performance in a challenging market environment in Europe and Switzerland. The increase also reflects the development of the cost of living as well as market salaries and wages for comparable employment.

Over the last few weeks, the Roche Employees Association (AVR) and the Roche Basel Works Council (AKR) held discussions at Roche regarding the adjustment of the 2016 payroll. Unfortunately, an agreement with the two associations could not be reached during the negotiations. The involved parties emphasise that the negotiations took place in a spirit of commitment, fairness and constructiveness.

The 0.9 percent payroll increase will be used to calculate the total amount available to managers for distribution to their staff in the form of individual, performance-based salary increases as of 1 April 2016.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.